Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Task Force’s PSA Proposal Prompts Calls For More Research On Prostate Cancer Diagnostics

This article was originally published in The Gray Sheet

Executive Summary

Overdiagnosis and overtreatment of prostate cancers that result from screening with prostate-specific antigen tests highlight the need for research on new diagnostics technologies, suggests a new draft statement from the U.S. Preventive Services Task Force.

You may also be interested in...

Molecular Diagnostics Moves Into Prostate Cancer

While the PSA test is still widely recognized as a valuable prostate cancer screening tool, its dismal accuracy record has created an acute need for more effective and informative alternatives, and the field of molecular diagnostics, based on gene-based biomarkers, is leading the charge.

PSA Prostate Cancer Screening Does More Harm Than Good, USPSTF Concludes

The final recommendations are a major shift in policy for the commonly performed blood test, and one certain to face ongoing controversy.

Research In Brief

Data and trial updates in cardiology, oncology and more.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts